DaltonBio HPV Test Kits
In February 2025, TruScreen partnered with Dalton Bioscience, a leading China based manufacturer of high-performance HPV DNA tests and laboratory equipment for cervical cancer screening, to distribute complementary HPV-related In Vitro Diagnostics (“IVD”) products through TruScreen’s global distribution network.
Combining TruScreen and HPV tests
TruScreen’s most recent clinical performance validation in Beijing, China - Assessment of the Real-Time Photoelectric Detection Device (TruScreen) in Screening for Cervical Precancerous Lesions in Middle-Aged Women: An Observational Study - has proven that sensitivity and specificity of cervical cancer screening can be improved when combining TruScreen with HR-HPV tests.
“TruScreen demonstrated good specificity (74.4%) and sensitivity (86.4%) for detecting CIN II or higher lesions, superior to those of TCT alone (sensitivity, 81.8%; specificity, 38.2%) and HPV testing alone (sensitivity, 81.8%; specificity, 28.2%).
When different testing methods were combined, the sensitivity of TCT+HR-HPV, TruScreen+HR-HPV, and TruScreen+HR-HPV+TCT reached 100%, while the highest specificity was observed with TruScreen+HR-HPV (25.6%).
”
About the DaltonBio DH series HPV Nucleic Acid Detection System and HPV Self Sampling Collection System
The DH3 kit is used to detect 14 high-risk HPV types that cause cervical cancer, provides relative viral load values, and it has clinical guiding significance for screening high-risk groups of cervical precancerous lesions.
DH3 can distinguish HPV-16/18 and achieve risk stratification management. The hybrid capture technology it applies does not require nucleic acid extraction and amplification, and has exceptional reproducibility and negative predictive value. The use of HPV full-length probes can effectively avoid missed diagnosis.
Talk to us
If you would like to discuss how TruScreen can support your market, we’d love to hear from you.
